Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACONNeuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) – International Society of Pediatric Oncology. Europe Neuroblastoma Group (SIOPEN) trial - Moreno, L (J Clin Oncol, 2019)
suppl; abstract